Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Auspex

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

Severe Asthma Patient Story

Streaming Well

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

- PMLiVE

Teva will have to endure revenue ‘trough’ in 2019

Company looks to migrane treatment Ajovy for growth

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Teva wins FDA OK for crucial migraine drug

Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

Getting the sizing right

Merger and Acquisition activity in our sector can learn from the natural world

- PMLiVE

Pfizer’s flat sales focus investor attention on M&A

But CEO Ian Reed insists that there is no need for a large-scale acquisition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links